Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Optimistic?

<< Previous

Bullboard Posts

Next >>

Comment by drippingsnoton Sep 10, 2020 2:45pm

206 Views

Post# 31534479

RE:RE:RE:Optimistic?

I don't think burning throug the money prior to making a deal (or a few deals) is an option - though it is a valid concern.

I think the comments that partnering deals are well underway is a good thing - but we're just not going to get the details until the deals are done.

I also think there are complications in deal making as ATE wants to generate more value before making deals - so - R&D is playing a very important (parallel) role.

We have 15 months from the time of the last financing - which realistincally means we need to see some good progress within 6 to 7 months to avoid coming face to face with this specific fear.

Let's see what they come up with.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver